GlobalData on MSN16h
J&J and Lilly both unveil IL-23 inhibitor efficacy in Crohn’s disease
After both receiving FDA approval in UC, J&J and Eli Lilly are racing for their IL-23 inhibitors to get the green light in ...
JNJ's subcutaneous Tremfya demonstrates efficacy in Crohn's
A phase 3 study found that a subcutaneous version of Johnson & Johnson's Tremfya (guselkumab) was effective in treating Crohn ...
dermatologyadvisor13h
Positive Results for Tremfya in Low Body Surface Area Psoriasis
Phase 3b trial evaluating Tremfya (guselkumab) in low body surface area plaque psoriasis found the treatment improved clearance.
Johnson & Johnson's Tremfya Seeks Expanded Use Approval After It Shares Encouraging Late-Stage Study Data In Crohn's Disease
On Monday, Johnson & Johnson (NYSE:JNJ) announced results from the Phase 3 GRAVITI study of Tremfya (guselkumab) for Crohn’s ...
New SPECTREM study findings reveal TREMFYA® (guselkumab) effectively clears overlooked and undertreated plaque psoriasis
Johnson & Johnson (NYSE: JNJ) announced today that treatment with TREMFYA® (guselkumab) resulted in clear or almost clear ...
Johnson & Johnson’s Tremfya shows efficacy in Crohn’s disease Phase 3 study
Johnson & Johnson announced results from the Phase 3 GRAVITI study of Tremfya – guselkumab -, the first and only IL-23 inhibitor, ...
The American Journal of Managed Care4d
Guselkumab Clears Skin in Psoriasis Resistant to Topicals
New phase 3b data reveal significant skin clearance in historically underserved patients with moderate plaque psoriasis, offering hope for improved treatment outcomes.
Medscape7d
Guselkumab Efficacy in Crohn's Disease Unaffected by Prior Biologic Use
In patients with moderate to severe Crohn’s disease, guselkumab showed similar efficacy in both biologic-naive and ...
Medscape7d
Guselkumab Provides Long-Term Relief in Psoriatic Arthritis
More than 90% of patients with PsA who received guselkumab every 8 weeks in the DISCOVER-2 trial maintained minimal ...
The Pharma Letter7d
J&J’s SC Tremfya could set new standard in Crohn's disease treatment
Tremfya (guselkumab) demonstrated strong results in the Phase III GRAVITI trial, marking a major breakthrough in the ...
Johnson & Johnson reports results from Phase 3b SPECTREM study
Johnson & Johnson announced that treatment with TREMFYA, or guselkumab, resulted in clear or almost clear skin in the majority of adults ...
WebMD13d
Tremfya Pen 200 Mg/2 Ml Subcutaneous Injector Monoclonal Antibody, Interleukin 23 Antagonists - Uses, Side Effects, and More
You may report side effects to Health Canada at 1-866-234-2345. Before using guselkumab, tell your doctor or pharmacist if you are allergic to it; or if you have any other allergies. This product ...